Panacea Biotec Ltd
PANACEABIOPanacea Biotec Ltd
PANACEABIO
Price Chart
Scorecard
Performance
AvgPrice return has been average, nothing exciting
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
AvgAverage profitability - not good, not bad
Entry point
AvgThe stock is not in the overbought zone
Red flags
LowNo red flag found
How to use scorecard? Learn more
Key Metrics
| No LabelNo Label | PB RatioPB Ratio | Dividend YieldDiv. Yield |
|---|---|---|
| -166.82 | 3.04 | — |
| Sector PESector PE | Sector PBSector PB | Sector Div YldSctr Div Yld |
|---|---|---|
| 52.21 | 6.78 | 0.51% |
Forecast & Ratings
Detailed Forecast Price
Price Upside
Earnings
Earnings Growth
Revenue
Rev. Growth
Company Profile
Panacea Biotec Limited is a health management company. The Company's principal business activity is the manufacture of allopathic pharmaceuticals preparations.
Peers
Compare with peersBiocon Ltd
Sai Life Sciences Ltd
Hester Biosciences Ltd
Zenotech Laboratories Ltd
Vivo Bio Tech Ltd
Get more out of Tickertape, Go Pro!
Customise key metrics, see detailed forecasts, download stock data and more
Forecasts
Price
Revenue
Earnings
Price Forecast
Hmm, looks like data is unavailable here. Please come back after some timeRevenue Forecast
Hmm, looks like data is unavailable here. Please come back after some timeEarnings Per Share Forecast
Hmm, looks like data is unavailable here. Please come back after some timeIncome
Balance Sheet
Cash Flow
Income Statement
| Financial Year | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | TTM | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 723.08 | 598.59 | 600.78 | 795.34 | 574.08 | 634.86 | 2,348.41 | 614.27 | 621.00 | 586.00 | ||||||||||
Raw Materials | 193.63 | 158.42 | 197.98 | 135.06 | 190.01 | 199.02 | 311.17 | 218.29 | 212.27 | 563.21 | ||||||||||
| Power & Fuel Cost | 25.15 | 30.55 | 33.52 | 34.55 | 29.74 | 30.94 | 37.82 | 31.95 | 35.95 | |||||||||||
| Employee Cost | 142.02 | 148.12 | 151.59 | 147.08 | 142.32 | 156.17 | 182.97 | 126.48 | 149.57 | |||||||||||
| Selling & Administrative Expenses | 104.35 | 86.07 | 68.92 | 94.77 | 83.69 | 75.20 | 102.87 | 70.56 | 70.78 | |||||||||||
| Operating & Other expenses | 76.21 | 73.74 | 57.06 | 179.67 | 88.77 | 88.30 | 39.60 | 110.63 | 110.66 | |||||||||||
EBITDA | 181.72 | 101.69 | 91.71 | 204.21 | 39.55 | 85.23 | 1,673.98 | 56.36 | 41.77 | 22.79 | ||||||||||
| Depreciation/Amortization | 73.32 | 67.95 | 57.28 | 54.00 | 43.22 | 45.59 | 43.78 | 39.12 | 36.71 | 35.33 | ||||||||||
| PBIT | 108.40 | 33.74 | 34.43 | 150.21 | -3.67 | 39.64 | 1,630.20 | 17.24 | 5.06 | -12.54 | ||||||||||
| Interest & Other Items | 127.33 | 100.93 | 100.58 | 104.83 | 173.98 | 185.34 | 180.84 | 4.44 | 3.58 | 3.52 | ||||||||||
| PBT | -18.93 | -67.19 | -66.15 | 45.38 | -177.65 | -145.70 | 1,449.36 | 12.80 | 1.48 | -16.06 | ||||||||||
| Taxes & Other Items | -0.64 | -12.70 | 7.84 | 7.65 | 16.61 | 1.99 | 371.04 | 46.04 | 2.65 | -0.70 | ||||||||||
| Net Income | -18.29 | -54.49 | -73.99 | 37.73 | -194.26 | -147.69 | 1,078.32 | -33.24 | -1.17 | -15.36 | ||||||||||
| EPS | -2.74 | -8.16 | -11.08 | 5.65 | -29.10 | -23.07 | 176.05 | -5.43 | -0.19 | -2.51 | ||||||||||
| DPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||||||
| Payout ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Company Updates
Annual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFAnnual report
PDFPeers & Comparison
Health CareBiotechnology
Valuation
Technical
Forecast
Compare valuation on Screener| Stock | PE RatioPE Ratio | PB RatioPB Ratio | Div. YieldDividend Yield |
|---|---|---|---|
| Panacea Biotec Ltd | -2,190.11 | 3.04 | — |
| Biocon Ltd | 43.07 | 1.74 | 0.14% |
| Sai Life Sciences Ltd | 187.49 | 15.92 | — |
| Hester Biosciences Ltd | 108.10 | 6.74 | 0.25% |
Price Comparison
Compare PANACEABIO with any stock or ETFShareholdings
Promoter Holdings Trend
Total Promoter Holding
In last 6 months, promoter holding in the company has almost stayed constant
Low Pledged Promoter Holding
Pledged promoter holdings is insignificant
Institutional Holdings Trend
Decreased Total Retail Holding
In last 3 months, retail holding in the company has decreased by 2.66%
Foreign Institutional Holding
In last 3 months, foreign institutional holding of the company has almost stayed constant
Shareholding Pattern
Dec 2023
Mar 2024
Jun 2024
Sep 2024
Shareholding History
smallcases
Looks like this stock is not in any smallcase yet.
Events
Dividend Trend
No Dividends
PANACEABIO has not given any dividends in last 5 years
Dividends
Corp. Actions
Announcements
Legal Orders
Upcoming Dividends
No upcoming dividends are available
Past Dividends
Cash Dividend
Ex DateEx DateSep 19, 2011
Dividend/Share
₹0.75
Ex DateEx Date
Sep 19, 2011
Cash Dividend
Ex DateEx DateSep 16, 2010
Dividend/Share
₹0.25
Ex DateEx Date
Sep 16, 2010
Panacea Biotec announced that the company's material subsidiary, Panacea Biotec Pharma (PBCL) has made further investment of US$ 9,25,000 (~Rs.7.92 crore) in its wholly owned subsidiary, Panacea Biotec Inc. (PB Inc.) subscription for 9,25,00,000 shares of common stock of PB Inc. at a price of US$ 0.01 per share. Panacea Biotec Inc. being a step-down subsidiary of the company. The investment made by PBPL in WOS is to facilitate the capex and working capital requirements of PB Inc. and is in furtherance of its business. The business of the WOS is in line with the business activities of the Company and PBPL. Powered by Capital Market - Live
The contract is worth $14.95 million (approximately Rs 127 crore). The said order will be executed by calendar year 2025, subject to signing of requisite amendment to the long term arrangement. The project entails supply of bOPV to UNICEF for its requirements in countries in Africa and Asia region as per the orders as may be received from time to time. Panacea Biotec is engaged in the business of research, development, manufacture, and marketing of branded pharmaceutical formulations in India and international markets. The company reported consolidated net loss of Rs 8.29 crore in Q2 FY24 as compared with net profit of Rs 15.70 crore reported in Q2 FY23. Net sales jumped 36.1% YoY to Rs 143.02 crore in Q2 FY24.Powered by Capital Market - Live
Panacea Biotec has received a Letter of Award from UNICEF for supply of 115 million doses of its bivalent oral polio vaccine (bOPV) worth ~US$ 14.95 million (~Rs.127 crore) in CY2025.Powered by Capital Market - Live
Net profit of Panacea Biotec reported to Rs 4.71 crore in the quarter ended September 2024 as against net loss of Rs 8.29 crore during the previous quarter ended September 2023. Sales rose 3.03% to Rs 147.35 crore in the quarter ended September 2024 as against Rs 143.02 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales147.35143.02 3 OPM %4.75-2.49 - PBDT10.67-1.24 LP PBT1.99-10.55 LP NP4.71-8.29 LP Powered by Capital Market - Live
Panacea Biotec will hold a meeting of the Board of Directors of the Company on 13 November 2024Powered by Capital Market - Live
Panacea Biotec announced that the Annual General Meeting (AGM) of the company will be held on 27 September 2024.Powered by Capital Market - Live
Net loss of Panacea Biotec reported to Rs 15.88 crore in the quarter ended June 2024 as against net profit of Rs 10.98 crore during the previous quarter ended June 2023. Sales declined 10.43% to Rs 115.72 crore in the quarter ended June 2024 as against Rs 129.19 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales115.72129.19 -10 OPM %-12.09-7.98 - PBDT-11.06-5.23 -111 PBT-19.79-14.71 -35 NP-15.8810.98 PL Powered by Capital Market - Live
Net loss of Panacea Biotec reported to Rs 13.78 crore in the quarter ended June 2024 as against net profit of Rs 1.29 crore during the previous quarter ended June 2023. Sales declined 36.38% to Rs 56.88 crore in the quarter ended June 2024 as against Rs 89.41 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales56.8889.41 -36 OPM %-18.447.62 - PBDT-9.906.69 PL PBT-14.981.29 PL NP-13.781.29 PL Powered by Capital Market - Live
Panacea Biotec will hold a meeting of the Board of Directors of the Company on 14 August 2024.Powered by Capital Market - Live
Johnson & Johnson’s dengue antiviral drug shows positive results
Lower than Industry Revenue Growth
Over the last 5 years, revenue has grown at a yearly rate of -4.83%, vs industry avg of 19%
Decreasing Market Share
Over the last 5 years, market share decreased from 10.44% to 3.41%